COLINZ LABORATORIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 41.4 INR | -0.41% |
|
-8.79% | +3.50% |
Valuation
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 66.74 | 29.76 | 40.82 | 34.74 | 107.6 | 160 |
| Enterprise Value (EV) 1 | 52.24 | 16.58 | 18.65 | -2.149 | 60.43 | 105.4 |
| P/E ratio | 29.2 x | 32.6 x | 31.3 x | 16.7 x | 31.8 x | 19.2 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 0.85 x | 0.39 x | 0.54 x | 0.56 x | 1.54 x | 2.24 x |
| EV / Revenue | 0.66 x | 0.22 x | 0.25 x | -0.03 x | 0.87 x | 1.47 x |
| EV / EBITDA | 14.6 x | 4.73 x | 6.16 x | -0.65 x | 10.3 x | 16.7 x |
| EV / FCF | 8.7 x | -5.24 x | 2.68 x | -0.2 x | 8.87 x | 17.8 x |
| FCF Yield | 11.5% | -19.1% | 37.3% | -506% | 11.3% | 5.62% |
| Price to Book | 0.99 x | 0.43 x | 0.6 x | 0.48 x | 1.4 x | 1.08 x |
| Nbr of stocks (in thousands) | 4,571 | 4,571 | 4,571 | 4,571 | 4,571 | 4,571 |
| Reference price 2 | 14.60 | 6.510 | 8.930 | 7.600 | 23.55 | 35.00 |
| Announcement Date | 7/31/18 | 10/16/19 | 9/2/20 | 8/30/21 | 8/24/22 | 8/29/23 |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 78.82 | 76.68 | 76.03 | 61.59 | 69.74 | 71.55 |
| EBITDA 1 | 3.587 | 3.507 | 3.027 | 3.331 | 5.862 | 6.326 |
| EBIT 1 | 1.376 | 1.348 | 1.079 | 1.418 | 3.85 | 5.037 |
| Operating Margin | 1.75% | 1.76% | 1.42% | 2.3% | 5.52% | 7.04% |
| Earnings before Tax (EBT) 1 | 1.513 | 1.557 | 1.761 | 2.452 | 4.803 | 5.998 |
| Net income 1 | 2.307 | 1.217 | 1.304 | 2.076 | 3.393 | 4.574 |
| Net margin | 2.93% | 1.59% | 1.72% | 3.37% | 4.87% | 6.39% |
| EPS 2 | 0.5000 | 0.2000 | 0.2854 | 0.4541 | 0.7400 | 1.820 |
| Free Cash Flow 1 | 6.006 | -3.162 | 6.952 | 10.87 | 6.811 | 5.93 |
| FCF margin | 7.62% | -4.12% | 9.14% | 17.65% | 9.77% | 8.29% |
| FCF Conversion (EBITDA) | 167.45% | - | 229.64% | 326.28% | 116.2% | 93.74% |
| FCF Conversion (Net income) | 260.39% | - | 532.93% | 523.56% | 200.75% | 129.65% |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 7/31/18 | 10/16/19 | 9/2/20 | 8/30/21 | 8/24/22 | 8/29/23 |
1INR in Million2INR
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 14.5 | 13.2 | 22.2 | 36.9 | 47.2 | 54.6 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | 6.01 | -3.16 | 6.95 | 10.9 | 6.81 | 5.93 |
| ROE (net income / shareholders' equity) | 3.48% | 1.79% | 1.91% | 2.94% | 4.53% | 5.78% |
| ROA (Net income/ Total Assets) | 0.89% | 0.9% | 0.75% | 0.94% | 2.4% | 3.12% |
| Assets 1 | 258.4 | 135.6 | 173.9 | 221.3 | 141.3 | 146.5 |
| Book Value Per Share 2 | 14.80 | 15.00 | 15.00 | 16.00 | 16.80 | 32.30 |
| Cash Flow per Share 2 | 0.5600 | 0.6000 | 0.9100 | 3.050 | 4.570 | 7.800 |
| Capex | - | - | 0.44 | 1.58 | 0.38 | - |
| Capex / Sales | - | - | 0.58% | 2.56% | 0.54% | - |
| Announcement Date | 7/31/18 | 10/16/19 | 9/2/20 | 8/30/21 | 8/24/22 | 8/29/23 |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +3.50% | 1.25M | |
| +21.28% | 44.4B | |
| +24.60% | 23.03B | |
| +19.22% | 15.14B | |
| +12.87% | 13.12B | |
| +44.67% | 11.85B | |
| -8.33% | 6.99B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +13.07% | 5.52B |
- Stock Market
- Equities
- COLINZ6 Stock
- Financials Colinz Laboratories Limited
